Rein Therapeutics (RNTX) Stock Price, News & Analysis

Company Overview

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Key Stats

• Today's Range: $1.36 to $1.55
• 50-Day Range: $1.45 to $2.36
• 52-Week Range: $1.35 to $4.40
• Volume: 111,270 shs
• Average Volume: 24,513 shs
• Market Capitalization: $32.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RNTX Stock Analysis - Frequently Asked Questions

How have RNTX shares performed this year?

Rein Therapeutics' stock was trading at $2.05 on January 1st, 2025. Since then, RNTX shares have decreased by 28.3% and is now trading at $1.47.
View the best growth stocks for 2025 here.

How were Rein Therapeutics' earnings last quarter?

Rein Therapeutics Inc. (NASDAQ:RNTX) issued its earnings results on Thursday, May, 15th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.04.

How do I buy shares of Rein Therapeutics?

Shares of RNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNTX
• CIK: 1420565
• Web: N/A
• Phone: (737) 802-1989
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$62.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -86.07%
• Return on Assets: -31.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.39
• Quick Ratio: 1.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.45 per share
• Price / Cash Flow: 3.24
• Book Value: $0.43 per share
• Price / Book: 3.42

Miscellaneous

• Outstanding Shares: 22,150,000
• Free Float: 21,024,000
• Market Cap: $32.56 million
• Optionable: N/A
• Beta: 1.30